Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Enveric Biosciences

< Previous 1 2 Next >
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences to Present at the Centurion One 5th Global Summit
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences to Present at H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Enveric Biosciences
Via Business Wire
Tickers ENVB
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback